Científicos españoles eliminan completamente el cáncer de páncreas en ratones

Reinforces EU scientific and medical research capabilities, particularly Spain's oncology expertise. Demonstrates continued European competitiveness in biomedical innovation against US and Asian research centers. Potential future pharmaceutical market advantage if treatment translates to human trials.

Similar to post-WWII European scientific recovery through institutions like CNIO, establishing research soft power and attracting international collaboration and investment.

Patients with pancreatic cancer could benefit from improved survival rates and reduced side effects if this therapy advances to human trials and approval. Healthcare costs may decrease long-term if treatment efficacy reduces hospitalization needs, though initial drug costs may be high.

Regulatory agencies (EMA, FDA) may prioritize accelerated review pathways for this therapy. Governments may increase R&D funding for oncology. Healthcare systems should prepare for potential integration of triple-therapy protocols. Patent protections and licensing agreements will likely follow.